StockMacro
Menu

Attovia Therapeutics

$15.10 -31% in 6 monthsMarket cap $690.3M

ATTO on XNAS, Health Care, Attovia Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

News coverage ran 14 times its usual week while shares rose 6.5% in a month.

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.

Industry
Biological products, (no diagnostic substances) (Health Care)
Website
attovia.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $22.3M.
Quarter to 31 Mar 2025: revenue –, net income -$15.2MQuarter to 30 Jun 2025: revenue $0, net income -$14.4MQuarter to 30 Jun 2025: revenue $0, net income -$14.4MQuarter to 30 Sep 2025: revenue $360K, net income -$13.8MQuarter to 30 Sep 2025: revenue $360K, net income -$13.8MQuarter to 31 Mar 2026: revenue –, net income -$18.7MQuarter to 30 Jun 2026: revenue $450K, net income -$20.7MQuarter to 30 Jun 2026: revenue $450K, net income -$20.7MQuarter to 30 Sep 2026: revenue $0, net income -$22.3MQuarter to 30 Sep 2026: revenue $0, net income -$22.3M
31 Mar 2025RevenueNet incomeNet losstallest bar $22.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$22.3M
30 Jun 2026$450K-$20.7M
31 Mar 2026–-$18.7M
30 Sep 2025$360K-$13.8M
30 Jun 2025$0-$14.4M
31 Mar 2025–-$15.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $395.9M $49.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $8.70
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.7 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Attovia TherapeuticsATTO (this company) $690.3M––––
Solid BiosciencesSLDB $697.6Mloss–––
Aura BiosciencesAURA $715.0Mloss–––
Monte Rosa TherapeuticsGLUE $738.3Mloss10.5-61%-186%
Iambic TherapeuticsIAM $621.4M––––
MeiraGTxMGTX $779.9M10.01.9+1366%19.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

88%

40.1M shares held by 13F filers (30 Sep 2026) of 45.7M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.5%

1.6M shares sold short (30 Oct 2026) of 45.7M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.5

1.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+9.2%

1.5M shares sold short in the report before, 1.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

63%

63% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 54%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

14

14 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

14×

14 articles in the last 7 days; its usual week has 1.

Price $15.10 on 20 Nov 2026, +3103% over 12 months (12-month range $13.73 to $25.55)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $39.8M in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $17K in the latest quarter, -95% on a year earlier.
Institutional holders (13F filers). 63 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
8 Aug 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 25.3M)
4 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
29 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
14 Jul 20268-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Aug 2026: $39.8M published
Revenue per quarter
Quarter ended 30 Jun 2025: $0; public on 3 Sep 2026
Quarter ended 30 Sep 2025: $360K; public on 10 Nov 2026
Quarter ended 30 Jun 2026: $450K; public on 3 Sep 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 10 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2025: $375K; public on 10 Nov 2026
Quarter ended 30 Sep 2026: $17K, -95% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
30 Sep 2026 report: 63; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $2.3M (13 Aug 2026), higher than 100% of its own history.
  • Clustered insider buying: had 3 insiders buy $25.3M of its shares on the open market within 30 days (3 filings) Public on 8 Aug 2026.
  • Revenue per quarter: Revenue $0 in the latest quarter, -100% on a year earlier.
  • Capital spending per quarter: Capital spending $17K in the latest quarter, -95% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 12 insider trades

No trades in the last 90 days; the latest was filed 13 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Aug 2026Goldman Sachs & Co. LLC and 7 othersFormer 10% OwnerSell105,807$21.28$2.3MForm 4
13 Aug 2026Goldman Sachs & Co. LLC and 7 othersFormer 10% OwnerBuy585,000$17.58$10.3MForm 4
10 Aug 2026venBio Global Strategic Fund IV, L.P.10% ownerBuy382,352$17.00$6.5MForm 4
7 Aug 2026Jeremy Green and 2 others10% ownerBuy600,000$17.00$10.2MForm 4
7 Aug 2026Sanofi10% ownerBuy300,000$17.00$5.1MForm 4
6 Aug 2026Fhmls Xi, L.P. and 2 others10% ownerBuy588,235$17.00$10.0MForm 4

63 institutions reported shares at the end of Q3 2026, 88% of the shares outstanding; 61 opened a position, 0 sold out. From 13F reports.

InstitutionShares% of companyValueChange
Frazier Life Sciences Management, L.P.7.0M15.4%$120.8M
Goldman Sachs Group Inc5.4M11.8%$92.4M
venBio Partners LLC4.2M9.15%$71.7M
Deep Track Capital, LP3.2M7.02%$55.0M
EcoR1 Capital, LLC2.0M4.43%$34.7M
Nextech Invest Ltd.1.8M4.01%$31.5M
Cormorant Asset Management, LP1.8M3.91%$30.7M
Redmile Group, LLC1.2M2.55%$19.9M
Commodore Capital LP1.2M2.54%$19.9M
Sanofi1.1M2.37%$18.6M

Company events

All 3 company events

In 12 months: 3 share registrations. Results releases and routine reports are left out.

FiledWhat happenedSource
4 Aug 2026Registered new securities for sale (S-1)S-1/A
29 Jul 2026Registered new securities for sale (S-1)S-1/A
14 Jul 2026Registered new securities for sale (S-1)S-1

The 5 newest of 94 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 29 Aug 2026Insiders record

    GOLDMAN SACHS ASSET MANAGEMENT, L.P. (Former 10% Owner) and 7 other(s) bought 585,000 shares of ATTO [amended] [same transaction as an earlier filing] (dated 28 Aug 2026)

  2. 29 Aug 2026Insiders record

    WALSH COLIN (director) bought 585,000 shares of ATTO [amended] [same transaction as an earlier filing] (dated 28 Aug 2026)

  3. 14 Aug 2026Insiders record

    WALSH COLIN (director) bought 585,000 shares of ATTO [same transaction as an earlier filing] (dated 13 Aug 2026)

  4. 14 Aug 2026Insiders record

    GOLDMAN SACHS & CO. LLC (Former 10% Owner) and 7 other(s) bought 585,000 shares of ATTO ($10.3M) (dated 13 Aug 2026)

  5. 11 Aug 2026Insiders record

    venBio Global Strategic Fund IV, L.P. (ten percent owner) bought 382,352 shares of ATTO ($6.5M) (dated 10 Aug 2026)

  6. 8 Aug 2026Insiders change

    had 3 insiders buy $25.3M of its shares on the open market within 30 days (3 filings).

    Who bought: Sanofi.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $25.3M
    Window
    9 Jul 2026 to 8 Aug 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  7. 8 Aug 2026Insiders record

    Green Jeremy (ten percent owner) and 2 other(s) bought 600,000 shares of ATTO ($10.2M) (dated 7 Aug 2026)

  8. 8 Aug 2026Insiders record

    Sanofi (ten percent owner) bought 300,000 shares of ATTO ($5.1M) (dated 7 Aug 2026)

  9. 7 Aug 2026Insiders record

    FHMLS XI, L.P. (ten percent owner) and 2 other(s) bought 588,235 shares of ATTO ($10.0M) (dated 6 Aug 2026)

  10. 4 Aug 2026Filings record

    Registered new securities for sale (S-1)

  11. 29 Jul 2026Filings record

    Registered new securities for sale (S-1)

  12. 14 Jul 2026Filings record

    Registered new securities for sale (S-1)

Not listed: 9 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002058707
Ticker
ATTO
Domain
attovia.com
Hq location
CA|SAN CARLOS|94070 (1 unverified)
Name
Attovia Therapeutics, Inc.
  • SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)8 records14 Jul 2026 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)54 data points31 Dec 2024 to 31 Oct 2026
  • SEC Form 4 insider transactions12 records, 16 data points6 Aug 2026 to 28 Aug 2026
  • FINRA short interest (twice monthly)416 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2652 data points1 Aug 2018 to 20 Nov 2026